Belgium-based pharmaceutical firm Mithra Pharmaceuticals has closed enrolment in the Phase III trial of its oral contraceptive Estelle in Europe and Russia.

Estelle is a combined oral contraceptive (COC) developed using 15mg of E4 and 3mg of DRSP.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The open-label single arm Phase III European trial will assess the safety and efficacy of Estelle in approximately 1,550 patients over a period of 12 months.

The firm has screened 1,709 patients to date and expects that a minimum of 1,550 will qualify for the enrolment in the study.

Mithra Pharmaceuticals chief executive officer Francois Fornieri said: "Initial studies have shown the potential advantages of Estetrol, including a reduction in side effects such as the risk of venous thromboembolism, an increase in body weight  and undesired bleeding whilst on the pill.

See Also:

"The firm has screened 1,709 patients to date and expects that a minimum of 1,550 will qualify for the enrolment in the study."

"We are on track to complete the trial in 2018 and hope to be able to provide women globally with a novel contraceptive option with a better safety and efficacy profile compared to currently available treatments.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study will assess the efficacy, cycle control and tolerance of the COC in patients aged between 18-50 years, 1,350 of which will be 18-35.

The trial's primary objective is to measure the number of pregnancies per 100 women every 12 months of exposure in patients aged 18-35.

With results expected by next year, the study is being conducted in around 69 centres across Europe and Russia.

A second Phase III study in the US and Canada began enrolment in September last year.